Intensity Therapeutics granted 180-day extension to regain Nasdaq compliance

Intensity Therapeutics (INTS) announced that it has been granted a 180 calendar day extension from The Nasdaq Stock Market to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, following the expiration of the initial 180 calendar day period to regain compliance on December 3, 2025, which was initially granted on June 6, 2025. The company now has until June 1, 2026 to meet the Minimum Bid Price Requirement set forth in Nasdaq Listing Rule 5550(a)(2).